ICI therapy is the backbone of immunotherapy aimed at enhancing the durable response and survival of patients with HCC and employs monoclonal antibodies targeting immune checkpoints, such as PD1 and PD-L1 (Cheng et al., 2020). Here, CD274 is linked to hepatocellular carcinoma.